effects of shenfu injection in the treatment of septic shock patients: a multicenter, controlled, randomized, open-label trial
Clicks: 133
ID: 184754
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
133 views
28 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #707 of 899 articles by views in ACS applied materials & interfaces
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 899 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The effect of Shenfu on biochemical parameters and survival during resuscitation in patients with septic shock was examined. This was a multicenter, controlled, randomized, open-label trial carried out in 210 patients with septic shock from seven medical centers in China. They were randomized to Shenfu or saline. The primary outcome was lactate clearance. The secondary outcomes were shock index normalization, dose of vasopressors, ICU stay, hospital stay, and mortality. A total of 199 patients completed the trial. Blood pressure, heart rate, and other routine lab tests showed no difference between the groups. Lactate levels and lactate clearance were similar between the two groups. Hospital and ICU stay were similar between the two groups. When considering all patients, the 7- and 28-day mortality were similar between the two groups, but when considering only patients with lactate levels ≥4.5 mmol/L, the Shenfu group showed a better 7-day survival than the control group (7 days: 83.3% versus 54.5%, P=0.034; 28 days: 72.7% versus 47.6%, P=0.092). Shenfu may improve the 7-day survival in patients with impaired lactate clearance (≥4.5 mmol/L), but the mechanism for this effect is unclear. Additional studies are necessary to characterize the hemodynamic changes after Shenfu infusion. This trial is registered with ChiCTR-TRC-11001369.
| Reference Key |
li2016evidence-basedeffects
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Yi Li;Xinchao Zhang;Peihong Lin;Haibo Qiu;Jie Wei;Yu Cao;Shuming Pan;Joseph Walline;Chuanyun Qian;Zhigang Shan;XueZhong Yu |
| Journal | ACS applied materials & interfaces |
| Year | 2016 |
| DOI |
10.1155/2016/2565169
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.